Recognized by Orthopedics This Week, app is designed to facilitate
patient compliance and improve spinal fusion outcomes
LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical
device company, today announced that its STIM
onTrack™ mobile app has earned the 2017 Spine Technology
Award in the Cervical Care category from Orthopedics This Week,
the most widely read publication in the Orthopedics industry. The award
will be presented today at the North American Spine Society (NASS)
annual meeting in Orlando, FL. and published in upcoming issues of Orthopedics
This Week and Orthopedics This Month Spine.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171025005064/en/
STIM onTrack mobile app for use with Orthofix CervicalStim and SpinalStim bone growth stimulators. (Photo: Business Wire)
The STIM onTrack technology for mobile devices was introduced in 2017
and works with the latest generation OrthofixCervicalStim™
and SpinalStim™
bone growth stimulators. The mobile app includes a first-to-market
feature that enables physicians to receive real-time data on how their
patients are adhering to their prescribed treatment, allowing them to
adjust and personalize follow-up protocols to help achieve better
outcomes. In parallel, the app provides patients with a daily treatment
reminder and a device usage calendar to help them adhere to their
prescription and take an active role in their spinal fusion recovery.
The STIM onTrack app is free and available through the iTunes App Store.
The STIM onTrack technology is one of 10 medical device advancements
being recognized by Orthopedics This Week that represent
significant advancements in their respective categories.
"The Spine Technology Awards are intended to bring increased recognition
to exemplary and innovative spine surgery products and the engineering
teams and inventors who create them," said Robin Young, Founder and
Publisher of Orthopedics This Week and RRY Publications. "We are
pleased to present Orthofix with this award in recognition of the STIM
onTrack mobile app and its potential to facilitate therapy compliance
and ultimately improve patient outcomes."
"We are honored to accept this award on behalf of our team of dedicated
people who work hard every day to develop innovative technologies like
the STIM onTrack app," said Brad Niemann, President of the Orthofix
BioStim strategic business unit. "This new mobile application and our
latest generation CervicalStim and SpinalStim bone growth stimulators
are great examples of the merger between our products and technology
advancements that are designed to improve patient outcomes. We are proud
to partner with physicians to help patients redefine their recovery
process through better tracking and adherence to their therapy."
About Bone Growth Stimulators
Orthofix announced the U.S. Food and Drug Administration (FDA) and
European CE Mark approval of its next-generation CervicalStim and
SpinalStim bone growth stimulators in January 2017. The U.S. devices
feature the STIM onTrack mobile app. These Class III medical devices use
a low-level pulsed electromagnetic field (PEMF) designed to activate
cellular pathways that stimulate the proliferation and differentiation
of mesenchymal stem cells to augment the body's natural healing process,
providing patients with a safe, noninvasive treatment option for
promoting post-operative lumbar and cervical fusion.
The SpinalStim device is the only bone growth therapy device approved by
the FDA as both a lumbar spinal fusion adjunct to improve fusion
outcomes and as a non-surgical treatment for spinal pseudoarthrosis.
Additionally, the CervicalStim device is the only bone growth therapy
device approved by the FDA as a noninvasive, adjunctive treatment option
for improving cervical fusion outcomes in high risk patients. Together,
these devices are the number one prescribed bone growth stimulators for
spinal fusion.
In October 2016, The North American Spine Society (NASS) issued
first-of-its-kind coverage
recommendations for electrical bone growth stimulators. These
evidence-based coverage policy recommendations support the use of PEMF
stimulation devices as an adjunct to spinal fusion surgery.
Orthofix invites those attending the NASS Annual Meeting to visit Booth
#1500, Hall WE1 to learn more about the STIM onTrack mobile app and our
next-generation bone growth stimulation devices.
About Orthopedics This Week
Orthopedics
This Week, a four time winner of the MORE awards for
journalistic excellence, is dedicated to delivering breaking news,
analysis and commentary about the Orthopedics industry. Published 40
times a year, Orthopedics This Week covers what matters most in
healthcare through the distribution of unique and valuable
information to professionals who get up every day and work in the
orthopedic community.
About Orthofix
Orthofix International N.V. is a diversified, global medical device
company focused on improving patients' lives by providing superior
reconstructive and regenerative orthopedic and spine solutions to
physicians worldwide. Headquartered in Lewisville, TX, the company has
four strategic business units that include BioStim, Biologics, Extremity
Fixation and Spine Fixation. Orthofix products are widely distributed
via the company's sales representatives, distributors and subsidiaries.
In addition, Orthofix is collaborating on research and development
activities with leading clinical organizations such as Brown University,
Sinai Hospital of Baltimore, Cleveland Clinic, Texas Scottish Rite
Hospital for Childrenand MTF Biologics. For more information, please
visit www.orthofix.com.
Forward-Looking Statements
This communication contains certain forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements
concerning the projections, financial condition, results of operations
and businesses of Orthofix and its subsidiaries, are based on
management's current expectations and estimates and involve risks and
uncertainties that could cause actual results or outcomes to differ
materially from those contemplated by the forward-looking statements.
The forward-looking statements in this release do not constitute
guarantees or promises of future performance. Factors that could cause
or contribute to such differences may include, but are not limited to,
risks relating to: practices of health insurance companies and other
third-party payors with respect to reimbursement for our PEMF devices
and other risks described in the "Risk Factors" section of our Annual
Report on Form 10-K for the fiscal year ended December 31, 2016, as well
as in other reports that we file in the future. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. The
Company undertakes no obligation to update or revise the information
contained in this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171025005064/en/
Orthofix International N.V.
Mark Quick, 214-937-2924
Investor
Relations
markquick@orthofix.com
or
Denise
Landry, 214-937-2529
Media Relations
deniselandry@orthofix.com
Source: Orthofix International N.V.
News Provided by Acquire Media